Lilly didn't copy the playbook — they rewrote it.
| Stat | Value |
|---|---|
| Avg body weight loss with Zepbound 15mg over 72 weeks (SURMOUNT-1) | 22.5% |
| Weight loss with retatrutide in Phase 2 at 48 weeks | 24.2% |
| Hormonal pathways targeted by tirzepatide (GLP-1 + GIP) | 2 |
| Hormonal pathways targeted by retatrutide (GLP-1 + GIP + glucagon) | 3 |
Key Takeaways
- Tirzepatide (Mounjaro): FDA-approved for type 2 diabetes — a dual GIP/GLP-1 agonist that outperforms GLP-1-only drugs on weight loss at matched doses.
- Tirzepatide (Zepbound): The same molecule as Mounjaro, approved specifically for obesity — delivered 22.5% average body weight loss at the highest dose in SURMOUNT-1.
- Orforglipron / Foundayo: First oral non-peptide GLP-1 agonist — no fasting requirement, significant competitive advantage over Rybelsus.
- Retatrutide: Triple agonist (GLP-1/GIP/glucagon) in Phase 3 — showed 24.2% weight loss in Phase 2, potentially the most effective obesity drug ever developed.
- Mechanism advantage: Adding GIP to GLP-1 appears to amplify fat cell activity and enhance the brain's satiety response beyond what GLP-1 alone achieves.
- Key limitation: Supply still catching up to demand; retatrutide is not yet approved and Phase 3 data will determine its future.
When tirzepatide entered clinical trials, researchers expected it to perform slightly better than semaglutide. The 22.5% average weight loss figure from SURMOUNT-1 was not expected. It forced the entire field — including Novo Nordisk — to recalibrate. Here's what Lilly has built, how the mechanism actually works, and where their pipeline is going.
The GIP Difference: Why Dual Agonism Changes the Math
GLP-1 alone is impressive. Add GIP and the picture changes.
GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone released from the gut after eating. For years, it was considered less important than GLP-1 for metabolic control — partly because people with type 2 diabetes often show impaired GIP response. Tirzepatide's developers made a counterintuitive bet: that stimulating both receptors simultaneously would be synergistic rather than just additive.
They were right. The dual mechanism appears to enhance insulin secretion more robustly than GLP-1 alone, improve insulin sensitivity in fat tissue, and amplify central nervous system signals that drive appetite suppression. The net effect is greater weight loss at equivalent doses — and SURMOUNT-1 proved it definitively. At 15mg weekly over 72 weeks, participants lost an average of 22.5% of body weight. About 1 in 3 lost 25% or more. For context, Wegovy's headline number from STEP 1 was 14.9%.
Mounjaro (Tirzepatide): The Diabetes Entry Point
Mounjaro launched the tirzepatide era in 2022.
FDA-approved for type 2 diabetes management in May 2022, Mounjaro is a weekly subcutaneous injection available in doses from 2.5mg up to 15mg. The SURPASS trial program compared tirzepatide head-to-head against several established T2D drugs, including semaglutide 1mg (Ozempic). In SURPASS-2, tirzepatide at 10mg and 15mg produced greater HbA1c reductions and greater weight loss than semaglutide 1mg — a direct comparison that made the clinical difference unmistakable.
Like Ozempic, Mounjaro became associated with off-label weight loss use almost immediately after launch. That off-label demand created the same supply pressure Novo Nordisk had experienced. It also accelerated Lilly's timeline on the next approval.
Zepbound (Tirzepatide for Obesity): The Weight Loss Approval
Same drug. Same doses. A separate FDA approval changed everything.
Zepbound was approved for chronic weight management in November 2023, following the SURMOUNT trial program. SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The results across all three tirzepatide doses — 5mg, 10mg, and 15mg — were consistently strong, but the 15mg arm drew the most attention: 22.5% average body weight loss over 72 weeks, with a placebo-subtracted effect of about 20 percentage points.
SURMOUNT-2 extended the data to people with type 2 diabetes and obesity — a population where GLP-1 drugs generally produce lower weight loss than in non-diabetic patients. Even here, tirzepatide at 15mg achieved 15.7% weight loss, which exceeded Wegovy's performance in its comparable T2D subgroup trial.
SURMOUNT-4 addressed the discontinuation question directly: participants who lost weight on tirzepatide for 36 weeks were randomized to either continue or switch to placebo. Those who continued lost an additional 5.5% of body weight; those who switched to placebo regained about two-thirds of what they'd lost. This confirms what clinicians already suspected — these medications are long-term commitments, not short-term courses.
Zepbound is prescribed on a dose escalation schedule starting at 2.5mg weekly for four weeks, then increasing in 2.5mg increments every four weeks until reaching the target dose. This gradual escalation manages gastrointestinal side effects — nausea, vomiting, diarrhea — which affect a meaningful minority of users in the early weeks but typically subside by the time the maintenance dose is reached.
Orforglipron (Foundayo): The Oral Breakthrough
A pill that doesn't require fasting is a different product entirely.
Orforglipron, approved under the brand name Foundayo, is the first oral non-peptide GLP-1 receptor agonist. Unlike Rybelsus (oral semaglutide), which is a peptide drug requiring special absorption technology and a strict fasting protocol, orforglipron is a small molecule. Small molecules absorb readily in the gut without needing to avoid food — which removes the most significant compliance barrier that limited Rybelsus's practical appeal.
In Phase 3 trials, orforglipron achieved HbA1c reductions comparable to injectable GLP-1 drugs in people with type 2 diabetes, with weight loss of around 9–10% at higher doses. That's lower than Zepbound's headline numbers, but the comparison isn't entirely fair — orforglipron is a GLP-1-only agonist (not dual GIP/GLP-1), and the convenience of a once-daily pill without food restrictions opens the therapy to a much wider population who wouldn't or couldn't use injectables.
The no-fasting requirement is genuinely important. In clinical practice, many patients on Rybelsus struggle with the 30-minute pre-meal window, especially when travel, morning routines, or work schedules are irregular. Foundayo eliminates that entirely.
Retatrutide: The Triple Agonist Still in Trials
The most ambitious molecule in Lilly's portfolio isn't approved yet.
Retatrutide activates three receptors simultaneously: GLP-1, GIP, and glucagon. Adding glucagon receptor agonism introduces a mechanism that directly increases energy expenditure — essentially raising the metabolic "burn rate" at rest. GLP-1 and GIP handle appetite suppression and insulin response; glucagon agonism adds a fat mobilization signal on top.
Phase 2 data, published in the New England Journal of Medicine in 2023, showed 24.2% average weight loss at the highest dose (12mg weekly) over 48 weeks. That number hasn't been seen before in a clinical trial of this scale. The placebo group lost about 2.1%, making the drug effect roughly 22 percentage points — larger than any approved therapy to date.
Phase 3 trials are underway. The unknowns are tolerability at scale and long-term safety data — particularly around the glucagon component, which introduces cardiovascular and hepatic considerations that require careful monitoring in larger, longer trials.
How Lilly's Products Compare to Each Other
| Drug | Mechanism | Delivery | Approved For | Weight Loss (avg) |
|---|---|---|---|---|
| Mounjaro | GLP-1 + GIP | Weekly injection | T2D | ~15–21% at 15mg |
| Zepbound | GLP-1 + GIP | Weekly injection | Obesity | ~22.5% at 15mg |
| Foundayo (orforglipron) | GLP-1 only | Daily oral (no fasting) | T2D (obesity approval pending) | ~9–10% |
| Retatrutide | GLP-1 + GIP + glucagon | Weekly injection | Phase 3 / Not yet approved | ~24.2% (Phase 2) |
The Supply Reality
Strong efficacy data and actual availability are two different things.
Mounjaro and Zepbound have both experienced supply constraints since launch, driven by demand that outpaced Lilly's manufacturing scale-up. The situation has improved through 2025, but patients in some regions still face delays, and pharmacy availability varies. Lilly has announced significant manufacturing investments, including new U.S. production facilities specifically for tirzepatide.
Cost without insurance mirrors the broader GLP-1 market: Zepbound's list price runs in the $1,000–$1,100 per month range. Lilly has maintained a savings card program that significantly reduces out-of-pocket cost for commercially insured patients, and Zepbound vials (as opposed to autoinjector pens) were introduced at lower price points specifically for cash-pay patients.
Frequently Asked Questions
What is the difference between Mounjaro and Zepbound?
They are the same drug — tirzepatide — at the same doses. The difference is the FDA-approved indication. Mounjaro is approved for type 2 diabetes management. Zepbound is approved for chronic weight management in adults with obesity or overweight with a weight-related health condition. Insurance coverage often depends on which indication applies to you.
How does tirzepatide outperform semaglutide on weight loss?
Tirzepatide targets both GLP-1 and GIP receptors, while semaglutide targets GLP-1 only. The dual mechanism appears to produce stronger appetite suppression and greater effects on fat tissue than GLP-1 receptor activation alone. In head-to-head trials, tirzepatide consistently produced larger weight reductions than semaglutide at comparable doses.
Does Foundayo (orforglipron) require fasting like Rybelsus?
No. Unlike Rybelsus (oral semaglutide), which requires an empty stomach and 30 minutes before food or other medications, orforglipron can be taken without fasting. This is one of its primary practical advantages over the competing oral GLP-1 option.
When will retatrutide be available?
Retatrutide is in Phase 3 clinical trials as of 2025–2026. It is not yet FDA-approved. If Phase 3 trials replicate the Phase 2 weight loss results and the safety profile holds up, an approval application could potentially be filed in 2026–2027, with approval to follow if the data support it.
Is Zepbound covered by insurance?
Coverage varies significantly by insurer, employer plan, and state. Some commercial plans cover Zepbound for obesity with prior authorization; others exclude obesity medications entirely. Coverage for Mounjaro (T2D indication) is generally broader. Lilly's savings programs can reduce monthly costs for eligible patients with commercial insurance.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment.
